查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1628079

数位治疗市场机会、成长动力、产业趋势分析和 2024 年至 2032 年预测

Digital Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 to 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 169 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球数位治疗市场将于2023 年达到89 亿美元，预计2024 年至2032 年复合年增长率为31.5%。中的日益集成。数位疗法利用经过临床验证的软体直接向患者提供医疗干预措施，帮助治疗和管理各种健康状况。

对管理慢性病的创新解决方案以及预防保健和健康疗法的需求不断增长，是一个关键的市场驱动力。对个人化医疗保健的日益关注以及具有健康意识的个人数量的不断增加扩大了对 DTx 的需求，为其未来的扩张奠定了坚实的基础。

市场分为软体和设备，到 2032 年，软体部分预计将以 31.7% 的复合年增长率成长。 。这些平台符合以患者为中心的医疗保健的转变以及数据驱动的治疗策略日益重要的趋势。改进的分析能力也支持客製化的治疗计划，提高患者的治疗效果。

市场范围
开始年份 2023年
预测年份 2024-2032
起始值 89 亿美元
预测值 1,041 亿美元
复合年增长率 31.5%

根据应用，数位治疗市场分为糖尿病、心血管疾病、肥胖、高血压、心理健康和失眠。其中，在全球糖尿病盛行率不断上升的推动下，糖尿病细分市场预计在 2024 年至 2032 年期间将以 31% 的复合年增长率成长。数位疗法透过提供即时监测、药物追踪和生活方式指导的工具在糖尿病管理中发挥着至关重要的作用，从而提高依从性和患者的整体健康状况。

北美将在2023 年主导数位治疗市场，预计2024 年至2032 年复合年增长率为30.7%。政策。美国在该地区处于领先地位，私营和公共部门都进行了大量投资，进一步推动了 DTx 解决方案的采用。该地区的医疗保健提供者越来越多地将数位疗法整合到护理计划中，以改善患者的治疗效果并降低医疗成本。

随着技术的不断进步和支持性的监管框架，北美有望保持在数位治疗市场的前沿，为创新和采用树立基准。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 慢性病盛行率增加
      • 成本控制的需求不断增加
      • 提高护理服务品质的潜力
      • 数位疗法日益普及
    • 产业陷阱与挑战
      • 安全和隐私问题
      • 缺乏熟练的 IT 专业人员
  • 成长潜力分析
  • 监管环境
    • 我们
    • 欧洲
  • 技术景观
    • 核心技术
    • 邻近技术
  • 未来市场趋势
  • 差距分析
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场：按组成部分，2018 - 2032

  • 主要趋势
  • 软体
  • 装置

第 6 章：市场：依应用划分，2018 - 2032

  • 主要趋势
  • 糖尿病
  • 肥胖
  • 心血管
  • 心理和行为健康
  • 高血压
  • 失眠
  • 其他的

第 7 章：市场：依销售管道划分，2018 - 2032

  • 主要趋势
  • 企业对企业 (B2B)
  • 企业对消费者 (B2C)

第 8 章：市场：按地区划分，2018 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 墨西哥
  • MEA
    • 南非
    • 沙乌地阿拉伯

第 9 章：公司简介

  • Otsuka Holdings Co., Ltd
  • LifeScan Inc.
  • Teladoc Health
  • Omada Health Inc.
  • Pear Therapeutics, Inc.
  • Propeller Health (ResMed)
  • Teladoc Health
简介目录
Product Code: 5408

The Global Digital Therapeutics Market reached USD 8.9 billion in 2023 and is projected to grow at a CAGR of 31.5% from 2024 to 2032. This remarkable growth is fueled by rapid advancements in healthcare technology and the increasing integration of digital health solutions in managing chronic diseases. Digital therapeutics leverage clinically validated software to deliver medical interventions directly to patients, aiding in the treatment and management of various health conditions.

Rising demand for innovative solutions to manage chronic diseases, alongside preventive care and wellness therapies, is a key market driver. A growing focus on personalized healthcare and the increasing number of health-conscious individuals amplify the demand for DTx, setting a strong foundation for its future expansion.

The market is segmented into software and devices, with the software segment anticipated to grow at a CAGR of 31.7% through 2032. Software-based DTx solutions, primarily accessed via mobile applications, offer unparalleled convenience by enabling real-time feedback, remote monitoring, and personalized care. These platforms align with the shift towards patient-centric healthcare and the rising importance of data-driven treatment strategies. Improved analytics capabilities also support tailored therapeutic plans, enhancing patient outcomes.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$8.9 Billion
Forecast Value$104.1 Billion
CAGR31.5%

Based on application, digital therapeutics market is classified into across diabetes, cardiovascular diseases, obesity, hypertension, mental health, and insomnia. Among these, the diabetes segment is expected to grow at a CAGR of 31% during 2024-2032, driven by the increasing global prevalence of diabetes. Digital therapeutics play a crucial role in managing diabetes through tools that offer real-time monitoring, medication tracking, and lifestyle guidance, thereby improving adherence and overall patient health.

North America dominated the digital therapeutics market in 2023, with a projected CAGR of 30.7% from 2024 to 2032. Factors contributing to this dominance include a well-established healthcare infrastructure, widespread adoption of smartphones, and regulatory policies that foster digital health innovation. The U.S. leads the region with substantial investments from both private and public sectors, further driving the adoption of DTx solutions. Healthcare providers in the region increasingly integrate digital therapeutics into care plans to enhance patient outcomes and lower healthcare costs.

With continuous advancements in technology and a supportive regulatory framework, North America is poised to remain at the forefront of the digital therapeutics market, setting benchmarks for innovation and adoption.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of chronic diseases
      • 3.2.1.2 Rising need for cost containment
      • 3.2.1.3 Potential to increase quality of care delivery
      • 3.2.2.4 Growing popularity of digital therapeutics
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Security and privacy issues
      • 3.2.2.2 Lack of skilled IT professionals
  • 3.3 Growth potential analysis
    • 3.3.1 By component
    • 3.3.2 By application
    • 3.3.3 By sales channel
  • 3.4 Regulatory landscape
    • 3.4.1 U.S.
    • 3.4.2 Europe
  • 3.5 Technological landscape
    • 3.5.1 Core technologies
    • 3.5.2 Adjacent technologies
  • 3.6 Future market trends
  • 3.7 Gap analysis
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market, By Component, 2018 - 2032 (USD Million)

  • 5.1 Key trends
  • 5.2 Software
  • 5.3 Device

Chapter 6 Market, By Application, 2018 - 2032 (USD Million)

  • 6.1 Key trends
  • 6.2 Diabetes
  • 6.3 Obesity
  • 6.4 Cardiovascular
  • 6.5 Mental & Behavioral health
  • 6.6 Hypertension
  • 6.7 Insomnia
  • 6.8 Others

Chapter 7 Market, By Sales Channel, 2018 - 2032 (USD Million)

  • 7.1 Key trends
  • 7.2 Business-to-Business (B2B)
  • 7.3 Business-to-Consumers (B2C)

Chapter 8 Market, By Region, 2018 - 2032 (USD Million)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
  • 8.6 MEA
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia

Chapter 9 Company Profiles

  • 9.1 Otsuka Holdings Co., Ltd
  • 9.2 LifeScan Inc.
  • 9.3 Teladoc Health
  • 9.4 Omada Health Inc.
  • 9.5 Pear Therapeutics, Inc.
  • 9.6 Propeller Health (ResMed)
  • 9.7 Teladoc Health